Results 51 to 60 of about 7,464 (222)

Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

BMC Nephrology, 2020
Background Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD).
José Ramón Santos, Ana Merino, Walter E. Haefeli, Cristina Miranda, Marisol Prats, Ioana Bancu, Lucía Bailón, José Moltó   +7 more
doaj   +1 more source

Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials [PDF]

, 2014
Background. Contemporary antiretroviral treatment regimens are simpler than in the past, with lower pill burden and once-daily dosing frequency common. We performed a meta-analysis of randomized controlled trials (RCTs) to investigate the impact of pill ...
Dowdy, David W., Gallant, Joel E., Giordano, Thomas P., Gross, Robert, Mills, Edward J., Mugavero, Michael J., Nachega, Jean B., Parienti, Jean-Jacques, Sax, Paul E., Uthman, Olalekan A.   +9 more
core   +4 more sources

A multidisciplinary, AI‐supported quality improvement intervention to manage polypharmacy in aging people with HIV

HIV Medicine, EarlyView.
Abstract Objectives Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older ...
Jovana Milic, Antonia Pugliese, Michela Belli, Gian Luca Lonardi, Caterina Ruffilli, Tommaso Albano, Marco Visicaro, Martina Ricciardetto, Pierluigi De Cosmo, Chiara Mussi, Francesca Gandolfi, Cristina Mussini, Costantino Grana, Giovanni Guaraldi   +13 more
wiley   +1 more source

Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

Drugs in Context, 2019
The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for HIV and cancer patients. To address this, current literature and guidelines suggest the continuation of antiretroviral therapy (ART) with oral oncolytic agents to ...
Melissa E Badowski, Bradley Burton, Kristy M Shaeer, John Dicristofano   +3 more
doaj   +1 more source

Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals. [PDF]

, 2017
Our study aimed to investigate the short-term effect of combination antiretroviral therapy (cART) on cognitive performance and functional and structural connectivity and their relationship to plasma levels of antiretroviral (ARV) drugs.
Arduino, Roberto C, Luque, Amneris, Ma, Qing, Mapstone, Mark, Miller, Eric, Qiu, Xing, Schifitto, Giovanni, Tivarus, Madalina, Wang, Lu, Weber, Miriam, Zhong, Jianhui, Zhuang, Yuchuan   +11 more
core   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies. [PDF]

, 2017
BACKGROUND: Antiretroviral therapy in human immunodeficiency virus (HIV)-infected women and blacks merits particular scrutiny because these groups have been underrepresented in clinical trials.
Bekker, Linda-Gail, DiNubile, Mark J, Katlama, Christine, Leavitt, Randi Y, Rodgers, Anthony J, Sklar, Peter A, Squires, Kathleen E., Teppler, Hedy, Yazdanpanah, Yazdan, Zhou, Yan   +9 more
core   +3 more sources

Effectiveness and Persistence of Long‐Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

Journal of the International AIDS Society, Volume 29, Issue 4, April 2026.
ABSTRACT Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV‐1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long‐acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain. Methods This multicentre cohort study across 58
Jara Llenas‐García, María del Mar Arcos Rueda, Ruth Calderón Hernaiz, Roberto Pedrero Tomé, Otilia Bisbal Pardo, Mariano Matarranz, Miguel Torralba, María José Galindo Puerto, Adrián Rodríguez, María Peñaranda Vera, Isabel Sanjoaquín Conde, Sara de la Fuente Moral, Alfonso Cabello‑Úbeda, Carolina Navarro San Francisco, Karenina Antelo Cuéllar, Marc Pedrosa Aragón, María Aguilera García, Juan Tiraboschi, Rosa María Martínez Álvarez, María Jesús Vivancos, Carmen Montero Hernández, Enrique Bernal Morell, Noemí Cabello‐Clotet, Luis Enrique Morano Amado, Laura Gisbert Pérez, María Antonia Sepúlveda, María Remedios Alemán Valls, Antonio Jesús Sánchez Guirao, Chiara Fanciulli, Cristina Escrig, Eva María Ferreira Pasos, Ana Lucas‐Dato, Sara García Torras, Carmen Hidalgo Tenorio, Miriam Estébanez, Magdalena Muelas‑Fernandez, Juan Emilio Losa García, Ana Cerezales Calviño, María Elisa Pino Díaz, Clara Martínez Montes, Víctor Arenas García, Francisco Arnaiz de las Revillas, Hadrián Pernas Pardavila, Sergio Padilla, María Ángeles Garcinuño Jiménez, Lucía Alonso Alonso, Noemí Ramos Vicente, Patricia Noemí Barragán Gallo, Rebeca Cabo Magadan, Míkel del Álamo, Miguel Vicente Egido Murciano, Alberto Juárez Toquero, Alberto Romero Palacios, Marta Clavero Olmos, María del Mar García Navarro, José Sanz, Juan Carlos Gainzarain, Marta Milian Sanz, Beatriz de la Calle, Oscar Luis Ferrero Benéitez, Jesús Troya, Luis Buzón‐Martín, The RELATIVITY Group   +62 more
wiley   +1 more source

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS

HIV/AIDS: Research and Palliative Care, 2016
Jordi Navarro, Adrian Curran Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is
Navarro J, Curran A
doaj  

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V.   +155 more
core   +4 more sources